AMCP and its members advocate for bipartisan legislation that eliminates bureaucratic barriers to high-quality, innovative therapies, while lowering the bill footed by patients, families, government, employers, and other healthcare payers.
People with rare diseases often have mental health challenges related to their health care. These vary by disease, but there are common issues that make it difficult for individuals and their families, including delays in getting diagnosed, not knowing what will happen in the future, having limited treatments, and facing financial difficulties.
View our Market Insights webinar that features a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable.
With President Trump and his administration returning to Washington, D.C., and a new Congress set to take shape, there’s naturally some uncertainty when it comes to the future of American health care policy. Looking ahead to 2025, however, there will likely be some key decisions affecting and defining how managed care pharmacy and the larger health care system operate and serve patients.
AMCP shared comments with Centers for Medicare & Medicaid Services (CMS) on the proposed 2026 Policy and Technical Changes to the Medicare Advantage (MA) Program. We applaud CMS’ efforts to address obesity and emphasized the importance of managing costs. AMCP urged CMS to issue guidance on managing drugs in this class to effectively treat obesity as a chronic disease. On the Medicare Transaction Facilitator, we advised CMS to avoid adding unnecessary costs and administrative burdens. We support CMS’ focus on increasing access to generics, biosimilars, and other affordable medications. Lastly, we provided insights on proposed changes to Star Ratings, ensuring member perspectives are represented.